Blueprint and Roche take on Lilly as FDA approves RET-target...

Cancer drugs firm Blueprint Medicines has gained a second US approval, with its Gavreto (pralsetinib) daily pill that targets non-small cell lung cancer with RET fusion mutations.<

In the precision medicine era, the line between products and...

Protein Misfolding Drug Discovery Summit

Discover & Translate Disease-Modifying Therapeutics

Highlight Therapeutics trials second-line melanoma combo aft...

Cancer immunotherapy has set new standards in care, with some impressive responses in those patients lucky enough to respond.

TIGIT Therapies Digital Summit

Harnessing TIGIT Checkpoint Inhibitor Therapies

NICE recommends regular NHS funding for Roche's lymphoma dru...

NICE has recommended regular NHS funding for Roche’s Polivy in certain lymphoma patients in final draft guidance, overturning a previous rejection.